Back to top
more

Ingevity (NGVT)

(Delayed Data from NYSE)

$42.00 USD

42.00
400,023

+0.21 (0.50%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $42.00 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (142 out of 250)

Industry: Chemical - Specialty

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ingevity to Lower Costs in Response to Coronavirus Outbreak

by Zacks Equity Research

Ingevity's (NGVT) cost-reduction measures will allow it to stay within the revised guidance range set out in its earnings release for the first quarter of 2020.

Ingevity Corporation (NGVT) Up 3.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Ingevity Corporation (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ingevity Gains on Capa Buyout Amid Weak Industrial Demand

by Zacks Equity Research

While Ingevity (NGVT) is exposed to weakness in industrial specialties, it is gaining from the Capa acquisition.

Ingevity (NGVT) Earnings & Revenues Surpass Estimates in Q1

by Zacks Equity Research

Ingevity (NGVT) expects sales for 2020 to be between $1.1 billion and $1.2 billion.

Ingevity Corporation (NGVT) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 33.33% and 9.99%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Ingevity Corporation (NGVT) Q1 Earnings Expected to Decline

by Zacks Equity Research

Ingevity Corporation (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ingevity to Gain From Capa Buyout & Regulation-driven Demand

by Zacks Equity Research

While Ingevity (NGVT) is exposed to cost pressures, and weakness in industrial specialties and oilfield applications, it should gain from the Capa acquisition.

Here's Why You Should Hold Onto Ingevity (NGVT) Stock Now

by Zacks Equity Research

Let's find out why specialty chemicals and materials maker Ingevity (NGVT) is worth retaining at the moment.

Ingevity Provides Update in Response to Coronavirus Outbreak

by Zacks Equity Research

Ingevity's (NGVT) first quarter is going better than anticipated despite modest headwinds from the coronavirus outbreak.

Anindya Barman headshot

Coronavirus, Tariffs Mar Chemical Specialty Industry Outlook

by Anindya Barman

Weak demand and raw material supply disruptions due to coronavirus as well as hefty trade tariffs pose as headwinds to the chemical specialty industry.

Why Is Ingevity Corporation (NGVT) Down 23.9% Since Last Earnings Report?

by Zacks Equity Research

Ingevity Corporation (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ingevity (NGVT) Authorizes Share Repurchase Worth $500M

by Zacks Equity Research

Ingevity's (NGVT) new authorization provides it with the flexibility to be opportunistic through 2020.

New Strong Sell Stocks for February 6th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Ingevity (NGVT) Q4 Earnings Surpass Estimates, Sales Miss

by Zacks Equity Research

While Ingevity (NGVT) faced challenges from continued macroeconomic pressure in the fourth quarter, it gained from growth in end-use applications.

Ingevity Corporation (NGVT) Q4 Earnings Beat Estimates

by Zacks Equity Research

Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 12.24% and -0.24%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Ingevity Corporation (NGVT) Up 2.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Ingevity Corporation (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Anindya Barman headshot

Near-Term Prospects Gloomy for Specialty Chemical Stocks

by Anindya Barman

Trade tariffs and raw material cost inflation pose as headwinds to the chemical specialty industry.

Ingevity's (NGVT) Earnings Top Estimates in Q3, Sales Miss

by Zacks Equity Research

While Ingevity (NGVT) faced challenges from weak market conditions in Q3, it gained from the Capa caprolactone acquisition.

Ingevity Corporation (NGVT) Q3 Earnings Beat Estimates

by Zacks Equity Research

Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 2.82% and -1.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Ingevity Corporation (NGVT) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Ingevity Corporation (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AXTA vs. NGVT: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

AXTA vs. NGVT: Which Stock Is the Better Value Option?

Ingevity Corporation (NGVT) Down 20.7% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ingevity Corporation (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ICL or NGVT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ICL vs. NGVT: Which Stock Is the Better Value Option?

ICL vs. NGVT: Which Stock Is the Better Value Option?

by Zacks Equity Research

ICL vs. NGVT: Which Stock Is the Better Value Option?

Ingevity's (NGVT) Earnings Beat Estimates in Q2, Sales Lag

by Zacks Equity Research

Ingevity (NGVT) gains from inorganic and organic growth strategy in Q2. The company reaffirms guidance for 2019.